Bioequivalence of Two Formulations of a CGRP Receptor Antagonist in Healthy Adults

Phase 1, randomised, open-label trial in migraine (2 arms), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time curve from time zero extrapolated to infinite time at 72 hours, Area under the plasma concentration-time curve from time zero to time of last measurable concentration at 72 hours and 1 more. Started May 2026; status: completed.